CN114752529B - Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof - Google Patents
Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof Download PDFInfo
- Publication number
- CN114752529B CN114752529B CN202210472568.8A CN202210472568A CN114752529B CN 114752529 B CN114752529 B CN 114752529B CN 202210472568 A CN202210472568 A CN 202210472568A CN 114752529 B CN114752529 B CN 114752529B
- Authority
- CN
- China
- Prior art keywords
- strain
- hom3201
- lactobacillus plantarum
- viable bacteria
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 96
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 96
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 96
- 241000894006 Bacteria Species 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 53
- 239000008103 glucose Substances 0.000 claims abstract description 53
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 241000700159 Rattus Species 0.000 claims abstract description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 21
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 230000001580 bacterial effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 8
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 8
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 8
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 7
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000002068 microbial inoculum Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 description 21
- 239000001963 growth medium Substances 0.000 description 16
- 238000002955 isolation Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000009630 liquid culture Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 7
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 7
- 241000186604 Lactobacillus reuteri Species 0.000 description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 7
- 102100040918 Pro-glucagon Human genes 0.000 description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940001882 lactobacillus reuteri Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 6
- 235000021109 kimchi Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 235000021110 pickles Nutrition 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 235000011293 Brassica napus Nutrition 0.000 description 2
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000002792 antioxidant assay Methods 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000012599 radical scavenging assay Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 101150022075 ADR1 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- -1 DPPH free radical Chemical class 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum HOM3201 strain, a viable bacteria preparation containing the same, and a preparation method and application thereof. The preservation number of the lactobacillus plantarum HOM3201 strain is CGMCC No.22700. The lactobacillus plantarum HOM3201 strain can obviously reduce the fasting blood glucose level of rats with insulin resistance glucose/lipid metabolic disorder models, increase the tolerance of organisms to glucose and reduce the insulin resistance index.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum (Lactobacillus plantarum) HOM3201 strain, a viable bacteria preparation containing the same, and a preparation method and application of the viable bacteria preparation.
Background
The World Health Organization (WHO) defines probiotics as active microorganisms that are beneficial to the host when consumed in sufficient quantities. Only strains that have been found to be beneficial to health through scientific research can be referred to as "probiotics". The core characteristics of probiotics are a sufficient number, a viable bacterial status and a beneficial health function. Lactobacillus plantarum (Lactobacillus plantarum) is a ubiquitous probiotic and is often separated from fermented foods such as pickled vegetables and pickle and human bodies. Lactobacillus plantarum has beneficial effects in improving intestinal barrier, diabetes, hypertension, obesity, anti-infection, mental diseases, etc.
The incidence of type 2 diabetes is rising year by year, with china in the leading part of the world. The etiology and pathogenesis of type 2 diabetes mellitus are extremely complex, and the defects of insulin resistance and insulin secretion of peripheral tissues mainly caused by genetic and environmental factors are considered to cause relative or absolute deficiency of insulin of organisms, so that the utilization of glucose is reduced, and hyperglycemia is caused to cause diabetes mellitus.
Current studies on probiotics to regulate blood glucose levels are incomplete and systematic.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a lactobacillus plantarum (Lactobacillus plantarum) HOM3201 strain, a live bacteria preparation containing the same, a preparation method and application.
In order to achieve the above object, the present invention provides the following technical solutions:
in one aspect, the invention provides a lactobacillus plantarum (Lactobacillus plantarum) HOM3201 strain, wherein the preservation number of the lactobacillus plantarum HOM3201 strain is CGMCC No.22700.
Preferably, the lactobacillus plantarum HOM3201 strain comprises the 16srDNA sequence represented by SEQ ID No. 1.
In another aspect, the invention provides a live bacterial formulation comprising a lactobacillus plantarum HOM3201 strain according to the description above.
Preferably, the live bacterial formulation comprises up to 4.0-8.0X10 11 CFU/g viable bacteria.
Preferably, the live bacteria preparation further comprises an auxiliary material.
In yet another aspect, the invention provides a food or nutraceutical comprising a viable bacterial formulation as described above.
In yet another aspect, the invention provides the use of lactobacillus plantarum HOM3201 strain as described above for the manufacture of a medicament for assisting in lowering blood glucose.
The lactobacillus plantarum HOM3201 strain is used for reducing the fasting blood glucose level of a rat with an insulin resistance glucose metabolism disorder/lipid metabolism disorder model, increasing the tolerance of an organism to glucose and reducing the insulin resistance index.
Preferably, the lactobacillus plantarum HOM3201 strain is used for the treatment of diabetes.
In yet another aspect, the present invention provides a method of preparing a viable bacterial preparation as described above, comprising the steps of: expanding the lactobacillus plantarum HOM3201 strain of claim 1 in an optimized liquid medium; collecting thalli; adding a protective agent for resuspension, vacuum freeze-drying, and crushing to obtain the active microbial inoculum.
The invention has the following advantages:
(1) The lactobacillus plantarum HOM3201 disclosed by the invention can obviously reduce the fasting blood glucose level of a rat with an insulin resistance glucose/lipid metabolic disorder model, increase the tolerance of an organism to glucose and reduce the insulin resistance index.
(2) The lactobacillus plantarum provided by the invention has an excellent in-vitro probiotics function. The strain has excellent resistance to artificial gastrointestinal fluids, bacteriostasis, antioxidation activity and the like.
(3) The active microbial inoculum has the advantages of simple production process parameters, short period, high viable count, good stability and long-term efficacy.
Drawings
FIG. 1 shows a graph of RAPD cluster analysis of Lactobacillus plantarum HOM3201 strain constructed based on UPGMA method.
FIG. 2 shows the inhibition of DPP-4 and alpha-glucosidase by Lactobacillus plantarum HOM3201 strain of the invention.
FIG. 3 shows the effect of Lactobacillus plantarum HOM3201 strain of the invention on glucose tolerance in rats, model of insulin-resistant glucose/lipid metabolism disorder.
Fig. 4 shows a process flow diagram of the present invention.
Description of the preservation of microorganisms
The lactobacillus plantarum (Lactobacillus plantarum) HOM3201 strain of the invention is preserved in China general microbiological culture Collection center (CGMCC) for culture Collection of microorganisms at 2021, 6 and 11 days, and the preservation address is as follows: the national institute of microbiology, national institute of sciences, 1 st, g.d.3, north Chen, west, chat, of the Chao, of Beijing, city; the preservation number is CGMCC No.22700.
Detailed Description
The invention discloses strains, characteristics and application, and one skilled in the art can refer to the content of the invention to properly improve the technological parameters. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this invention, without departing from the spirit or scope of the invention.
Dipeptidyl peptidase 4 inhibitors (i.e., DPP-4 inhibitors) are a novel class of drugs for the treatment of type 2 diabetes, such as sitagliptin, vildagliptin, and the like. DPP-4 inhibitors can inhibit the activity of DPP-4, thereby stimulating the secretion of incretins [ glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) ]. GLP-1 and GIP can inhibit glucagon release, increase insulin secretion, reduce gastric emptying, and lower blood glucose levels.
The alpha-glucosidase inhibitor is an oral hypoglycemic agent for type 2 diabetes mellitus, and is mainly acarbose and voglibose which are commonly used. The mechanism of reducing blood glucose of the alpha-glucosidase inhibitor is that the speed of decomposing starch into glucose is slowed down by inhibiting alpha-glucosidase on intestinal mucosa, and the absorption of glucose by small intestine is reduced and delayed, so that the blood glucose is reduced, and the effect on postprandial hyperglycemia is obvious. Alpha-glucosidase inhibitors do not stimulate insulin secretion, and such drugs alone typically do not induce hypoglycemia, and thus can help reduce fluctuations in blood glucose.
The lactobacillus plantarum HOM3201 disclosed by the invention can obviously reduce the fasting blood glucose level of a rat with an insulin resistance glucose/lipid metabolic disorder model, increase the tolerance of an organism to glucose and reduce the insulin resistance index. The hypoglycemic mechanism is that lactobacillus plantarum HOM3201 is grown and metabolized to produce DPP-4 inhibitor and alpha-glucosidase inhibitor. DPP-4 inhibitors stimulate the body to produce glucagon-like peptide-1 (GLP-1) by inhibiting DPP-4, and promote insulin secretion; the alpha-glucosidase inhibitor can slow down the rate of converting starch into glucose by inhibiting alpha-glucosidase, thereby achieving the purpose of reducing blood glucose.
In order to make the technical problems to be solved, the technical scheme adopted and the advantages of the invention more clear, the invention will be described in detail with reference to the accompanying drawings and specific embodiments. The following examples are illustrative of the invention and are not intended to limit the scope of the invention.
The experimental methods used in the present invention are all conventional methods unless otherwise specified.
The reagents and materials used in the present invention, unless otherwise specified, are formulated conventionally or commercially available.
Kimchi used in the present invention:
the kimchi sample used in the present invention for separating lactobacillus plantarum HOM3201 strain was from home-made hand kimchi in all households of the province of Sichuan. The manufacturing method comprises the following steps: cleaning vegetables (green turnip, white turnip, carrot, cabbage, cowpea, green pepper, etc.), cutting into strips, and air drying; cleaning pickle jar, air drying, and pouring a little high-degree white spirit for disinfection; pouring clear water into an oilless pot, adding cortex Cinnamomi Japonici, herba Pelargonii Graveolentis, fructus Zanthoxyli, fructus Anisi Stellati, crystal sugar, and rhizoma Zingiberis recens, boiling, thoroughly cooling, pouring into a pickle jar, and pouring Zanthoxylum piperitum juice, jowar wine and vegetables. After the cover is buckled, clean water is poured into the water tank to seal the jar. Fermenting in a cool and ventilated place for 10 days to obtain the pickle used in the invention.
The commercial strain of Lactobacillus plantarum used in the present invention was isolated from a commercial product containing the desired strain, as described in example 1.
EXAMPLE 1 isolation and identification of Lactobacillus plantarum HOM3201 Strain
(1) Lactobacillus plantarum strain screening culture medium formula
Improved MRS solid medium:
MRS medium (OXOID, CM 1163) was added with 0.05g bromocresol green (Shanghai Biotechnology) and double distilled water 1L, and the mixture was stirred well. Adjusting pH to 5.5, sterilizing at 121deg.C for 20 min.
(2) Isolation and screening of Lactobacillus plantarum Strain
Isolation and screening of HOM Lactobacillus plantarum Strain
1g of kimchi was weighed and 9mL of 0.9% physiological saline solution was used to prepare kimchi juice. Sucking 1mL of pickle juice, diluting the sample by using a 10-fold dilution method, wherein the dilution is 10 -3 -10 -5 . The diluted kimchi juice was coated on the above modified MRS plate and anaerobically cultured at 35℃for 72 hours. Single colonies with wet and smooth surfaces, neat edges, milky yellow or milky white colonies and yellow circumferences are selected, streaked, cultured and purified. And simultaneously gram staining and microscopic examination are carried out to observe colony morphology. Transferring single colony into MRS liquid culture medium for pure culture, and culturing with glycerol to obtain 5 lactobacillus plantarum strains, which are named HOM3201, HOM3202, HOM3203, HOM3204, and HOM3205.
b. Isolation and screening of commercial strains of Lactobacillus plantarum
The lactobacillus plantarum commercial strain used in the invention is separated from commercial probiotics products, and the strain and product information are as follows: lactobacillus plantarum Lp-115 (isolated from Yineng 300), lactobacillus plantarum LP-ONLLY (isolated from Ondelia probiotic powder), lactobacillus plantarum P-8 (isolated from Yitanou), lactobacillus plantarum CCFM8661 (isolated from Yitanou and Mei), and Lactobacillus plantarum ST-III (isolated from Guangming Leun fermented milk).
Isolation method of commercial strains of lactobacillus plantarum: 1g of a commercial strain powder or fermented milk containing Lactobacillus plantarum was weighed and resuspended in 9mL of 0.9% physiological saline. 1mL of the sample is sucked, the sample is diluted by a 10-fold dilution method, 2-3 proper gradient dilutions are selected to be coated on a modified MRS plate, and the sample is cultured for 72 hours at 35 ℃. Single colonies with wet and smooth surfaces, neat edges, milky yellow or milky white colonies and yellow circumferences are selected, streaked, cultured and purified. And simultaneously gram staining and microscopic examination are carried out to observe colony morphology. Transferring single colony into MRS liquid culture medium for pure culture, and preserving glycerol.
(3) Identification of HOM Lactobacillus plantarum Strain
The strains are inoculated into MRS liquid culture medium, cultured for 48 hours at 35 ℃, bacterial total DNA is extracted from each bacterial liquid, 16S rDNA amplification is carried out, PCR amplification and agarose gel electrophoresis are carried out by utilizing universal primers 27F and 1492R, and the sequencing (Shanghai) is carried out after gel cutting recovery. Then, the above 5 strains HOM3201, HOM3202, HOM3203, HOM3204 and HOM3205 were identified as Lactobacillus plantarum by BLAST tool in NCBI database (Lactobacillus plantarum). Wherein the 16S rDNA of HOM3201 is shown as SEQ ID NO. 1.
The sequence of the 16S rDNA of HOM3201 was determined as follows:
CATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGTTTGAAAGATGGCTTCAGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTA
(4) Molecular biological characterization of Lactobacillus plantarum strains
The resulting Lactobacillus plantarum HOM3201 strain was subjected to genotyping comparison studies with Lactobacillus plantarum HOM3202, HOM3203, HOM3204 and HOM3205 strains, and with the commercial strains Lactobacillus plantarum Lp-115, LP-ONLLY, P-8, CCFM8661 and ST-III strains, using the random amplified polymorphic DNA marker (RAPD) method to determine the specificity of the resulting strains.
The genomic DNA of the strain was randomly amplified by selecting primers OPA-02, OPA-18, OPL-07, OPL-16 and OPM-05 as shown in Table 1 below. The amplification conditions were as follows: the template and primers were first kept at 95℃for 5min, then cooled to 56℃and the reaction mixture was added to amplify 45 cycles as follows: denaturation at 94℃for 1min, annealing at 30℃for 1min and extension at 72℃for 2min.
TABLE 1
| Primer(s) | Sequence(s) | SEQ ID NO |
| OPA-02 | 5’-TGCCGAGCTG-3’ | 2 |
| OPA-18 | 5’-AGGTGACCGT-3’ | 3 |
| OPL-07 | 5’-AGGCGGGAAC-3’ | 4 |
| OPL-16 | 5’-AGGTTGCAGG-3’ | 5 |
| OPM-05 | 5’-GGGAACGTGT-3’ | 6 |
| 27F | 5’-AGTTTGATCMTGGCTCAG-3’ | 7 |
| 1492R | 5’-GGTTACCTTGTTACGACTT-3’ | 8 |
mu.L of the PCR amplification product was detected by 2% agarose gel electrophoresis, followed by imaging in a gel imager. The RAPD patterns were clustered using Bionumerics version 6.6.6 software based on UPGMA method. The results are shown in FIG. 1.
It is generally considered that strains having a similarity of more than 90% in phylogenetic tree have the possibility of homozygotic strains. The phylogenetic tree results of this experiment show that the HOM3201 strain is not on one branch with other lactobacillus plantarum, the similarity is lower than 60%, and the significant difference exists. Thus, HOM3201 strain has genotype specificity and uniqueness compared to HOM3202, HOM3203, HOM3204 and HOM3205 strains, and commercial strains Lp-115, LP-ONLLY, P-8, CCFM8661 and ST-III strains.
Example 2 gastrointestinal trafficability test
(1) Isolation and activation of strains
Three commercial strains of lactobacillus plantarum 299V (isolated from the Jarrow probiotic product by the same method as in example 1 b. lactobacillus plantarum commercial strain isolation method), and the strains lactobacillus plantarum Lp-115 and lactobacillus plantarum ST-III isolated from the commercial probiotic product of example 1 were selected as positive controls in this experiment. Each strain was inoculated into MRS liquid medium, cultured at 37℃for 24 hours, and activated twice for use.
(2) Preparation of artificial gastric juice
16.4mL of dilute hydrochloric acid and 10g of pepsin are taken, about 800mL of water is added, the pH is regulated to 3.0 after shaking, water is added to a constant volume of 1L, and the mixture is filtered by a microporous filter membrane with the thickness of 0.22 mu m for later use.
(3) Preparation of artificial intestinal juice
Taking 6.8g of monopotassium phosphate, adding 500mL of water to dissolve the monopotassium phosphate, and adjusting the pH value to 6.8 by using 0.1mol/L sodium hydroxide solution; and dissolving 10g of pancreatin in a proper amount of water, mixing the two solutions, diluting to 1000mL with water, and filtering with a 0.22 μm sterile filter membrane under a sterile environment for later use.
(4) Evaluation of viability of Strain in simulated Artificial gastrointestinal fluids
Taking 1mL of bacterial liquid of each strain, centrifuging, collecting bacterial bodies, adding the bacterial liquid into 10mL of artificial gastric juice, uniformly mixing, immediately counting the number of viable bacteria, and marking as T 0 Culturing in a 37 deg.C incubator for 3 hr, counting viable bacteria, and counting as T 1 . Centrifuging the sample, adding 10mL of artificial intestinal juice, mixing, culturing in a 37 ℃ incubator for 3h to count viable bacteria, and recording as T 2 . The survival rate was calculated using the following formula:
wherein T is 0 The viable count CFU/mL of the test strain is 0h before the untreated; t (T) 1 The viable count of the tested strain after being treated by artificial gastric juice for 3 hours; t (T) 2 Is the viable count of the tested strain after 3h of treatment by artificial gastric juice and artificial intestinal juice.
TABLE 2 survival of Lactobacillus plantarum in simulated artificial gastrointestinal fluids
* : significant differences compared to HOM3201 group (p < 0.05)
* *: significant differences compared to HOM3201 group (p < 0.01)
As can be seen from table 2: after 3 hours of simulated artificial gastric juice treatment, the survival rate of the lactobacillus plantarum HOM3201 strain can reach 118.87%, and after the strain is continuously treated by 3 hours of simulated artificial intestinal juice treatment, the survival rate of the lactobacillus plantarum HOM3201 strain can still reach 122.59%, which indicates that the lactobacillus plantarum HOM3201 strain has higher survival rate in the gastrointestinal tract.
Lactobacillus plantarum HOM3201 is more resistant to gastric juice than the commercial lactobacillus plantarum 299V, LP-115, ST-III strains, and has a significant or very significant difference compared to the commercial lactobacillus plantarum 299V, LP-115, ST-III strains.
Example 3 test for the ability to inhibit common pathogenic bacteria
(1) Pathogenic bacteria activation
Five pathogenic bacteria are selected in the test: coli (e.coli) ATCC8739, salmonella typhimurium (Salmonella typhimurium) ATCC14028, staphylococcus aureus (Staphylococcus aureus) ATCC6538, pseudomonas aeruginosa (Pseudomonas aeruginosa) ATCC9027, listeria monocytogenes (Listeria monocytogenes) ATCC19111. These pathogenic strains were purchased from ATCC (american type culture collection ).
Pathogenic strains were inoculated into nutrient agar medium, respectively, and cultured at 37℃with shaking at 200rpm for 12 hours. The indicator bacteria were conditioned with fresh medium to od=0.1 for use.
(2) Lactic acid bacteria strain activation
In this experiment, commercial strains Lactobacillus plantarum 299V (isolation method is the same as examples 1 and 2), lp-115 (isolation method is the same as example 1), ST-III strain (isolation method is the same as example 1) and Lactobacillus rhamnosus (Lactobacillus rhamnosus) LGG strain was selected as control strain, wherein LGG strain was isolated from Kang Cui Le powder product, isolation method is the same as example 1.
And (3) inoculating the strains into an MRS liquid culture medium respectively, standing and culturing for 24 hours at 37 ℃, and activating twice to obtain strain fermentation liquor. Centrifugation at 11000rpm for 10min, taking supernatant for antibacterial test, and taking MRS liquid culture medium as negative control. Annotation: lactic acid bacteria are a general generic term comprising lactobacillus and bifidobacterium.
(3) Flat plate preparation
The sterilized nutrient agar is cultured and poured into a culture dish, 100 mu L of indicator bacteria liquid is added into a culture medium, and after uniform mixing, standing and solidification are carried out.
(4) Bacteriostasis experiment
The oxford cup was gently placed on the plate with sterile forceps and the holes were kept a distance apart. 150. Mu.L of fermentation supernatant was added to each well, and after diffusion in a refrigerator at 4℃for 12 hours, the mixture was cultured in an incubator at 37℃for 18 hours, and the diameter of the zone of inhibition was observed and measured.
TABLE 3 inhibitory Effect of Lactobacillus plantarum HOM3201 Strain on pathogenic bacteria
Note that: "-" has no antibacterial activity, < 11mm; the "+" is 11mm or less and the bacteriostasis area is 16mm or less; the "++" is 16mm or less and the bacteriostasis area is less than 23mm; "+". ++'s more than or equal to 23mm
As shown in Table 3, lactobacillus plantarum HOM3201 has inhibitory effect on all 5 pathogenic bacteria. Compared with commercial strains of lactobacillus plantarum 299V, lp-115, ST-III strain and lactobacillus rhamnosus LGG strain, the antibacterial capability is equivalent.
EXAMPLE 4 antibiotic susceptibility test
Drug susceptibility testing the K-B agar method recommended by the American clinical standards Committee (NCCLS) was followed as follows:
(1) As a control strain, a commercial strain Lactobacillus plantarum 299V, lp-115, ST-III strain (same as in example 3) was selected. The strains were inoculated into MRS liquid medium, cultured at 37℃for 24 hours, and activated continuously for 3 generations.
(2) 1mL of the bacterial liquid (1.5X10) 8 CFU/mL), 15mL of MRS solid culture medium are placed in a sterilization culture dish, uniformly mixed, stuck with standard antibiotic drug sensitive paper sheets after the flat plate is solidified, cultured for 24-48 hours at 37 ℃, and then the diameter of a bacteriostasis ring is measured and recorded. The results are shown in Table 4, interpreted according to the CLSI decision criteria.
TABLE 4 determination of the sensitivity of lactic acid bacterial strains to 9 antibiotics
S (susceptible) is sensitive; i (intermediate), medium; r (resistance) represents drug resistance.
As can be seen from Table 4, HOM3201 strain exhibited resistance to vancomycin, gentamicin, streptomycin, kanamycin, clindamycin, and was sensitive to chloramphenicol, tetracycline, ampicillin, and erythromycin. In contrast to the commercial strain Lactobacillus plantarum 299V, lp-115, ST-III strain, HOM3201 did not find abnormal resistance.
Example 5 antioxidant Activity assay
(1) Lactobacillus plantarum Strain activation
Commercial strains Lactobacillus plantarum Lp-115, ST-III strain (isolation procedure as in example 1) were selected as positive controls. Inoculating each strain into MRS culture medium, standing at 37deg.C for 24 hr, activating for 3 generations, centrifuging, and adjusting strain concentration to 3×10 10 CFU/mL for use.
(2) Antioxidant Activity assay
The indicators include total antioxidant capacity assay (T-AOC), hydroxyl radical scavenging assay (OH), DPPH radical scavenging assay. The first two indexes are measured according to the operation instruction by using a kit purchased by Nanjing built company. The DPPH free radical scavenging test adopts a colorimetric method, and the principle is that the free radical scavenger provides a lone pair electron pairing of an electron and DPPH free radical, so that the self purple color is changed into yellow, the absorbance at the wavelength of 517nm is reduced, the variation degree and the free radical scavenging degree are in a linear relation, namely, the stronger the scavenging capability of the free radical scavenger is, the smaller the absorbance is. The results are shown in Table 5.
TABLE 5 measurement of in vitro antioxidant Activity of Lactobacillus plantarum Strain
* : significant differences compared to HOM3201 group (p < 0.05)
* *: significant differences compared to HOM3201 group (p < 0.01)
As is clear from Table 5, lactobacillus plantarum HOM3201 strain showed remarkable effects in terms of total antioxidant capacity, hydroxyl radical scavenging and DPPH radical scavenging. In terms of T-AOC, HOM3201 strain performed excellently and had very significant differences compared to Lp-115 strain; no obvious difference exists among the three groups in terms of hydroxyl radical scavenging; in DPPH radical scavenging, HOM3201 strain scavenging rate is higher compared with Lp-115 strain, and has significant difference; there was no significant difference compared to the ST-III strain.
EXAMPLE 6 preparation Process of active bacterial powder of Lactobacillus plantarum HOM3201 Strain
(1) Culture of strains
Lactobacillus plantarum HOM3201 strain is inoculated in MRS liquid culture medium, cultured at 37 ℃ for 24 hours, and activated for 2 generations. Inoculating into fermentation medium (shown in Table 6), culturing at 37deg.C, and culturing at viable count of 2×10 10 CFU/mL or more.
TABLE 6 fermentation Medium formulation
(2) Preparation of freeze-drying protective agent
The protective agent containing 100g/L skimmed milk powder, 50g/L trehalose, 3g/L vitamin C and 5g/L L-sodium glutamate is prepared by mixing sterile water with protective agent raw materials.
(3) Freeze drying
Centrifuging fermentation broth of Lactobacillus plantarum HOM3201 strain to collect bacterial mud, washing bacterial mud with 0.9% sterile physiological saline, mixing bacterial mud with the protective agent to make bacterial liquid concentration reach 10 10 Freeze drying the above CFU/mL in a freeze dryer, and pulverizing the bacterial cake with a fine grinder to obtain the freeze-dried bacterial powder with viable count higher than 6.0X10 11 CFU/g。
Example 7 in vitro hypoglycemic efficacy and mechanism exploration of Lactobacillus plantarum HOM3201 Strain
(1) MRS liquid culture medium with improved configuration
MRS culture medium (OXOID), adding 0.05% L-cysteine hydrochloride based on the final culture medium, stirring, and sterilizing at 121deg.C for 20 min.
(2) Strain activation and sample processing
Commercial strains Lactobacillus plantarum 299V, lp-115, ST-III (isolation procedure same as example 1), and Lactobacillus reuteri (Lactobacillus reuteri) ADR1 strain were selected as positive controls, and ADR-1 strain was isolated from a Glycometole product by the same method as example 1.
The strains are respectively inoculated into fresh modified MRS liquid culture medium with the inoculum size of 1 percent, and are subjected to standing anaerobic culture for 24 hours at 37 ℃ and activated for 3 generations. The bacterial solution was centrifuged at 8000rpm for 10min and washed three times with Phosphate Buffered Saline (PBS). The number of viable bacteria is regulated to 4 multiplied by 10 10 CFU/mL, anaerobic culture for 8h, centrifuging at 8000rpm for 10min, and collecting supernatant.
(3) DPP-4 inhibitory and alpha-glucosidase inhibitory screening
In vitro screening for hypoglycemic function was performed using DPP-4 inhibitor screening kit (Abnova#KA1311) and alpha-glucosidase inhibitor screening kit (Biovision#K938). The inhibition ratio of the lactobacillus samples to the above two enzymes was calculated (see fig. 2 for the results).
TABLE 7 strains of the respective strainsInhibition rate of DPP-4 and inhibition rate of alpha-glucosidase
* : significant differences compared to HOM3201 group (p < 0.05)
As can be seen from Table 7, the HOM3201 strain has high inhibition rate on DPP-4 and alpha-glucosidase. In the DPP-4 inhibition assay, the HOM3201 strain group was higher than the other groups, and the HOM3201 group had a significant difference (P < 0.05) compared with the ADR-1, 299V strain group. In the α -glucosidase inhibition assay, the HOM3201 strain group was lower than the ADR-1 group, but all were higher than the other groups. Clinical literature studies have shown that lactobacillus reuteri ADR-1 strain has hypoglycemic efficacy. Taken together, HOM3201 strain achieves the goal of lowering blood glucose levels by producing higher levels of DPP-4 inhibitor and alpha-glucosidase inhibitor (fig. 2).
Example 8 Lactobacillus plantarum HOM3201 Strain stimulates GLP-1 secretion by NCI-H716 cells
(1) Culture of NCI-H716 cells
The experiment selects NCI-H716 cells (purchased from the cell bank of the national academy of sciences) and NCI-H716 cells were grown in RPMI-1640 (Gibco) medium containing 10% fetal bovine serum (Hyclone), 1% double antibody (penicillin and streptomycin, hyclone), 37℃and 5% CO 2 Cells were grown in suspension in the incubator of (C).
(2) Culture of lactic acid bacteria strains
Three commercial strains (lactobacillus reuteri ADR-1, lactobacillus rhamnosus LGG and bifidobacterium lactis (Bifidobacterium lactis) CECT 8145) were selected as positive controls. The bifidobacterium lactis CECT8145 strain was isolated from ADM corporation donor meal.
The separation method of bifidobacterium lactis CECT8145 comprises the following steps: 1g of the bacterial powder was weighed and resuspended in 9mL of 0.9% physiological saline. 1mL of the sample was aspirated, diluted by 10-fold dilution, and 2-3 suitable gradient dilutions were selected and plated on TOS (Merck, 1.00043.0500) plates for anaerobic incubation at 37℃for 72h. Selecting single milky colony with wet and smooth surface, regular edge, streaking culture and purification. And simultaneously gram staining and microscopic examination are carried out to observe colony morphology. Single colonies were transferred to mrs+0.5% cysteine hydrochloride (Sigma, 1161509) liquid medium for pure culture and glycerol stock.
Respectively inoculating lactobacillus plantarum HOM3201, lactobacillus reuteri ADR-1 and lactobacillus rhamnosus LGG into MRS liquid culture medium, standing at 37 ℃ for culturing for 24 hours, and activating for 3 generations; inoculating bifidobacterium lactis CECT8145 into MRS+0.5% cysteine hydrochloride liquid culture medium, standing at 37 ℃ for anaerobic culture for 24 hours, and activating for 3 generations; each broth was centrifuged at 8000rpm for 10min and washed three times with Krebs buffer (Sigma). The number of viable bacteria is regulated to be 1 multiplied by 10 10 CFU/mL, ready for use.
(3) GLP-1 endocrine experiments
NCI-H716 cells were grown at 1.5X10 6 Density of individual/well in matrigel coated 24 well plate (Corning), added to endocrine differentiation medium, 37 ℃,5% CO 2 Is cultured for 2 days, and an endocrine differentiation experiment is performed. Endocrine differentiation medium is high sugar DMEM (Gibco) medium containing 10% fetal bovine serum, 1% diabody.
After 2 days, the DMEM medium was replaced with Krebs-Ringer buffer containing 1X 10 each 10 After culturing the CFU/mL probiotic strain for 2 hours, centrifuging at 8000rpm for 10min, and collecting the supernatant. To the supernatant, 50. Mu.g/mL of phenylmethylsulfonyl fluoride (Roche) and 10. Mu.g/mL of sitagliptin (Sigma) were added, and then the concentration of GLP-1 was detected using ELISA kit (Raybiotech).
TABLE 8 stimulation of GLP-1 production by NCI-H716 cells by the strains
* : significant differences compared to HOM3201 group (P < 0.05)
* *: significant differences compared to HOM3201 group (P < 0.01)
Three commercial strains (lactobacillus reuteri ADR-1, lactobacillus rhamnosus LGG and bifidobacterium lactis CECT 8145) all have literature-demonstrated related studies with hypoglycemic activity.
As can be seen from Table 8, the HOM3201 strain stimulated NCI-H716 cells to secrete high levels of GLP-1 at concentrations of 1890.21 + -158.38 pg/mL. HOM3201 strain has very significant differences (p < 0.01) compared to lactobacillus reuteri ADR-1; in contrast to lactobacillus rhamnosus LGG and bifidobacterium lactis CECT8145, HOM3201 strain had significant differences (p < 0.05). The results indicate that lactobacillus plantarum HOM3201 strain has the effect of reducing blood sugar, and the sugar reducing mechanism is probably through stimulating intestinal canal L cells to produce high-content GLP-1.
Example 9 Effect of Lactobacillus plantarum HOM3201 Strain on insulin resistance by Tetraoxypyrimidine on rat blood glucose in a model of disorder of glucose/lipid metabolism
(1) Beijing Wanghua Fukang Biotechnology Co., ltd. [ license number: SCXK- (Beijing) 2019-0008] bred 140g-160g healthy SPF grade SD male rats, 46 experimental animals were bred in SPF grade animal room of health food function detection center of applied culture and application university of Beijing association university, and the use license number of the experimental animals: SYXK (Beijing) 2017-0038. Experiments were performed in two batches. Experiment a batch of 10 experiments were performed on the effects of fasting blood glucose in normal rats; experiment two 36 rats with the model of insulin resistance and glucose/lipid metabolism disorder induced by tetraoxypyrimidine were subjected to fasting glucose experiment; sugar tolerance experiments; serum triglyceride and total cholesterol experiments; serum insulin experiments. Wherein the formula of the high heat energy feed comprises: 52.6% of basic feed, 15% of sucrose, 15% of yolk powder, 10% of lard, 5% of casein, 1.2% of cholesterol, 0.2% of sodium cholate, 0.6% of calcium bicarbonate and 0.4% of stone powder.
(2) Normal rat fasting blood glucose effect experiment: the common feed is suitable for 3 days of feeding, fasted for 4 hours, blood is taken, after standing for 10 minutes, serum is separated by centrifugation for 10 minutes at 3000r/min, and the blood sugar value before glucose is given (namely 0 hour) and the blood sugar value after BW glucose is given by 2.5g/kg for 0.5 hour and 2 hours are measured by a biochemical analyzer to be used as the basic value of animals in the batch. Setting up a normal controlGroup (0 CFU/just) and HOM3201 group (5 x 10) 10 CFU/kg BW); each group of 5 rats was fasted for 4 hours after the end of the test, blood was collected from the inner canthus venous plexus, and the fasting blood glucose level was measured using a biochemical analyzer, and the body weight of the rats at the beginning and end was measured.
TABLE 9 influence of Lactobacillus plantarum HOM3201 Strain on normal rat body weight
As can be seen from table 9, the body weights of normal rats before and after the experiment were compared between the two groups, and the difference was not significant (P > 0.05).
TABLE 10 Effect of Lactobacillus plantarum HOM3201 Strain on fasting blood glucose in normal rats
As can be seen from table 10, there was no significant difference in blood glucose values between the two groups before and after the experiment (P > 0.05).
(3) Tetraoxypyrimidine-induced insulin resistant glucose/lipid metabolism disorder model rat fasting glucose assay: establishing a blank control group, a model group and a HOM3201 strain group, wherein each group comprises 12 mice, and the gastric lavage dosage of the HOM3201 strain group is 5 x 10 10 CFU/kg BW. The test substance was administered by the gavage method in an amount of 0.5mL per animal, and the blank control group and the model control group were administered with the same volume of physiological saline, and were gavaged once daily. After the basal feed is fed for one week, the model control group and the HOM3201 strain group are replaced by high-heat feed, and after the basal feed is fed for three weeks, the model control group and the HOM3201 strain group are fasted for 24 hours, and the tetraoxapyrimidine is fed by intraperitoneal injection for 105mg/kg BW, and the injection quantity is 1mL/100g body weight. The high heat feed was fed for 5 days after injection. At the end of the trial, rats of each group fasted4h, blood is taken, and fasting blood glucose, glucose tolerance, serum insulin, total cholesterol and triglyceride levels are detected.
TABLE 11 rat body weight measurement/>
As can be seen from table 11, there was no significant difference in body weight between the rats before and after the experiment in the model control group compared to the blank control group.
TABLE 12 blood sugar and glucose tolerance in rat models of glycolipid metabolism disorders
* *: has extremely significant difference compared with the blank control group (p < 0.01)
TABLE 13 blood lipid and insulin resistance index of rat glycolipid metabolism disorder model
* : compared with the blank control group, the difference is significant (p < 0.05)
As can be seen from tables 12 and 13, the model control group has very significant differences (P < 0.01) between the blood glucose values of 0h and 0.5h after glucose administration, and the blood glucose value of 0.5h of the model control group is not less than 10mmol/L, which indicates that the model sugar metabolism disorder is established. Comparing the model control group with the blank control group, wherein the serum total cholesterol rise has a significant difference (P < 0.05), and judging that the lipid metabolism disorder model is established; the model control group is compared with the blank control group, the insulin resistance index is obviously reduced (P is less than 0.05), and the comprehensive judgment of the insulin resistance glucose/lipid metabolism disorder model is successful.
TABLE 14 influence of HOM3201 Strain on model rat body weight
TABLE 15 influence of HOM3201 Strain on fasting blood glucose in model rats
* : compared with the model control group, the difference is significant (p < 0.05)
TABLE 16 influence of HOM3201 Strain on sugar tolerance in model rats
* : compared with the model control group, the difference is significant (p < 0.05)
As can be seen from tables 15 and 16, there was a significant difference in blood glucose levels between the two groups at 0h (p < 0.05), and there was a trend of decrease in blood glucose in HOM3201 group at 0.5h, but no significant difference (p > 0.05). At 2h, there was no significant difference between the two groups. This suggests that HOM3201 probiotics significantly reduced fasting blood glucose in the model rats, decreased postprandial blood glucose levels at 0.5h, and improved blood glucose tolerance (fig. 3).
TABLE 17 HOM3201 Strain versus model rat serum cholesterol and TriglyceridesInfluence of
As can be seen from table 17, there was no significant difference in serum cholesterol and triglycerides in HOM3201 strain group (P > 0.05) compared to model control group.
TABLE 18 influence of HOM3201 on serum insulin resistance index of model rats
As can be seen from Table 18, the HOM3201 strain group had a decrease in serum insulin resistance index, but the difference was not significant (P > 0.05) compared to the model control group.
Fig. 4 shows a flow chart of the process of isolation, screening, preparation of formulations, in vitro and hypoglycemic effect in animal experiments of lactobacillus plantarum HOM3201 strain of the present invention.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Although embodiments of the present invention have been disclosed above, it is not limited to the details of the description and the examples set forth, which are well suited to various fields of use, and further modifications may be readily apparent to those skilled in the art, and accordingly, the invention is not limited to the specific details and details shown and described herein, without departing from the general concepts defined in the claims and the equivalents thereof.
Claims (10)
1. A lactobacillus plantarum (Lactobacillus plantarum) HOM3201 strain, wherein the lactobacillus plantarum HOM3201 strain has a preservation number of CGMCC No.22700, and the lactobacillus plantarum HOM3201 strain is capable of producing a DPP-4 inhibitor and an alpha-glucosidase inhibitor, stimulating cells to secrete GLP-1, and has antioxidant activity.
2. The lactobacillus plantarum HOM3201 strain according to claim 1, wherein the lactobacillus plantarum HOM3201 strain comprises the 16s rDNA sequence represented by SEQ ID No. 1.
3. A live bacterial formulation comprising the lactobacillus plantarum HOM3201 strain of claim 1.
4. A viable bacteria preparation according to claim 3, characterized in that the viable bacteria preparation comprises up to 4.0-8.0 x 10 11 CFU/g viable bacteria.
5. The viable bacteria preparation of claim 3 or 4, further comprising an adjuvant.
6. A food or health product comprising the viable bacteria preparation according to any one of claims 3 to 5.
7. Use of a lactobacillus plantarum HOM3201 strain according to claim 1 in the manufacture of a medicament for assisting in lowering blood glucose.
8. The use according to claim 7, wherein lactobacillus plantarum HOM3201 strain is used for reducing fasting blood glucose levels, increasing glucose tolerance in the body and reducing insulin resistance index in rats with insulin resistant glucose metabolism disorder/lipid metabolism disorder models.
9. The use according to claim 7, characterized in that the lactobacillus plantarum HOM3201 strain is used for the treatment of diabetes.
10. A method of preparing the live bacterial formulation according to any one of claims 3 to 5, comprising the steps of:
expanding the lactobacillus plantarum HOM3201 strain of claim 1 in an optimized liquid medium;
collecting thalli;
adding a protective agent for resuspension, vacuum freeze-drying, and crushing to obtain the active microbial inoculum.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472568.8A CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
| KR1020230055044A KR20230154400A (en) | 2022-04-29 | 2023-04-26 | Lactobacillus plantarum hom3201 strain and its live bacterial preparation, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472568.8A CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114752529A CN114752529A (en) | 2022-07-15 |
| CN114752529B true CN114752529B (en) | 2023-12-19 |
Family
ID=82333809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210472568.8A Active CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20230154400A (en) |
| CN (1) | CN114752529B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350547B (en) * | 2021-12-17 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN116200310B (en) * | 2023-03-17 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for regulating intestinal hormone GLP-1 level and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN107502575A (en) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | One plant of Lactobacillus plantarum with the high inhibitory activity of α glucuroides |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN109810912A (en) * | 2017-11-21 | 2019-05-28 | 华大精准营养（深圳）科技有限公司 | One lactobacillus plantarum LH-511 and its application |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN113061543A (en) * | 2020-01-02 | 2021-07-02 | 北京科丽科技有限公司 | Lactobacillus plantarum and application thereof |
| CN114276953A (en) * | 2021-07-21 | 2022-04-05 | 重庆誉研生物科技有限公司 | Lactobacillus plantarum YE4 capable of inhibiting intestinal cell DPP-4 activity and application thereof in relieving diabetes |
| CN114317353A (en) * | 2021-12-30 | 2022-04-12 | 浙江大学 | Lactobacillus plantarum ZJUFYJ7 and application thereof |
-
2022
- 2022-04-29 CN CN202210472568.8A patent/CN114752529B/en active Active
-
2023
- 2023-04-26 KR KR1020230055044A patent/KR20230154400A/en not_active Application Discontinuation
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN107502575A (en) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | One plant of Lactobacillus plantarum with the high inhibitory activity of α glucuroides |
| CN109810912A (en) * | 2017-11-21 | 2019-05-28 | 华大精准营养（深圳）科技有限公司 | One lactobacillus plantarum LH-511 and its application |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN113061543A (en) * | 2020-01-02 | 2021-07-02 | 北京科丽科技有限公司 | Lactobacillus plantarum and application thereof |
| KR20210088408A (en) * | 2020-01-02 | 2021-07-14 | 코리 베이징 컴퍼니 리미티드 | Lactobacillus Plantarum and uses thereof |
| CN114276953A (en) * | 2021-07-21 | 2022-04-05 | 重庆誉研生物科技有限公司 | Lactobacillus plantarum YE4 capable of inhibiting intestinal cell DPP-4 activity and application thereof in relieving diabetes |
| CN114317353A (en) * | 2021-12-30 | 2022-04-12 | 浙江大学 | Lactobacillus plantarum ZJUFYJ7 and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity;Zhu Zeng等;Journal of Functional Foods;第20卷;第486-495页 * |
| 乳酸菌代谢物中二肽基肽酶 -4 抑制剂的分离纯化及鉴定;董杰等;食品科学;第41卷(第8期);第116-122页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114752529A (en) | 2022-07-15 |
| KR20230154400A (en) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114752529B (en) | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof | |
| CN108102959B (en) | Humanized lactobacillus plantarum ZY08 for reducing cholesterol and application thereof | |
| CN108076643B (en) | Lactobacillus rhamnosus bacteria for the treatment of e.g. bacterial vaginosis | |
| CN111849810B (en) | Lactobacillus ZJuuiss 03 for antagonizing helicobacter pylori and application thereof | |
| CN110157645B (en) | Lactobacillus salivarius Y4 and application thereof | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN116004456B (en) | Lactobacillus reuteri A21325 for inhibiting helicobacter pylori infection and application thereof | |
| CN113061543A (en) | Lactobacillus plantarum and application thereof | |
| CN117327608A (en) | Lactobacillus rhamnosus strain and application thereof | |
| CN114480231A (en) | Lactobacillus reuteri for resisting helicobacter pylori infection and application thereof | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN113528367B (en) | Bacillus coagulans with functions of preventing diarrhea and degrading cholesterol | |
| CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| CN111743158A (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| CN116421632A (en) | Application of pediococcus acidilactici in preparing food, health-care product or medicine with lipid-lowering effect | |
| WO2019174002A1 (en) | Pediococcus pentosaceus ccfm1012, food fermented thereby and use thereof in preparation of medicine for antagonizing campylobacter jejuni infection | |
| CN113430153B (en) | Lactobacillus reuteri ZJuuds 09 for reducing blood pressure and application thereof | |
| CN113528383B (en) | Hypoglycemic lactobacillus ZJUIDS09 and application thereof | |
| CN116396890B (en) | Lactobacillus plantarum ZJUIDS15 for preventing and treating colon cancer and application thereof | |
| CN117264850B (en) | Pediococcus pentosaceus SW006 with auxiliary treatment of colpitis and immunity enhancing functions and application thereof | |
| CN114395514B (en) | Lactobacillus acidophilus, microbial inoculum and application thereof | |
| Jikang et al. | Characterization and in vitro properties of Lactobacillus plantarum and Leuconostoc mesenteroides for probiotic potential and nitrite degradation. | |
| CN117327604A (en) | Live bacterial preparation containing lactobacillus rhamnosus strain and application thereof | |
| CN117323349A (en) | Composition comprising lactobacillus rhamnosus strain and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |